Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

Safety and Immunogenicity of Zoster Vaccine Live in HIV-Infected Adults with CD4+ Cell Counts Above 200 Cells/mL Virologically Suppressed on Antiretroviral Therapy.

Benson CA, Andersen JW, Macatangay BJC, Mailliard RB, Rinaldo CR Jr, Read S, Bozzolo DR, Purdue L, Jennings C, Keefer MC, Glesby M, Tebas P, Russell AF, Martin J, Annunziato P, Popmihajlov Z, Lennox JL.

Clin Infect Dis. 2018 Mar 26. doi: 10.1093/cid/ciy242. [Epub ahead of print]

PMID:
29590326
2.

CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3-36 months with HIV infection.

Bolton Moore C, Capparelli EV, Samson P, Bwakura-Dangarembizi M, Jean-Philippe P, Worrell C, Heckman B, Purdue L, Spector SA, Benns A, Borkowsky W, Loftis A, Hawkins E, Wallis C, Chadwick EG; IMPAACT P1070 team.

AIDS. 2017 May 15;31(8):1129-1136. doi: 10.1097/QAD.0000000000001463.

PMID:
28323755
3.

Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention.

Fowler MG, Qin M, Fiscus SA, Currier JS, Flynn PM, Chipato T, McIntyre J, Gnanashanmugam D, Siberry GK, Coletti AS, Taha TE, Klingman KL, Martinson FE, Owor M, Violari A, Moodley D, Theron GB, Bhosale R, Bobat R, Chi BH, Strehlau R, Mlay P, Loftis AJ, Browning R, Fenton T, Purdue L, Basar M, Shapiro DE, Mofenson LM; IMPAACT 1077BF/1077FF PROMISE Study Team.

N Engl J Med. 2016 Nov 3;375(18):1726-1737.

4.

The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1.

Jacobson JM, Bosinger SE, Kang M, Belaunzaran-Zamudio P, Matining RM, Wilson CC, Flexner C, Clagett B, Plants J, Read S, Purdue L, Myers L, Boone L, Tebas P, Kumar P, Clifford D, Douek D, Silvestri G, Landay AL, Lederman MM.

AIDS Res Hum Retroviruses. 2016 Jul;32(7):636-47. doi: 10.1089/AID.2015.0336. Epub 2016 Apr 19.

5.

Comparison of the Prevalences and Diversities of Listeria Species and Listeria monocytogenes in an Urban and a Rural Agricultural Watershed.

Stea EC, Purdue LM, Jamieson RC, Yost CK, Truelstrup Hansen L.

Appl Environ Microbiol. 2015 Jun;81(11):3812-22. doi: 10.1128/AEM.00416-15. Epub 2015 Mar 27.

6.

Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.

Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS; ACTG A5257 Team.

Ann Intern Med. 2014 Oct 7;161(7):461-71. doi: 10.7326/M14-1084. Erratum in: Ann Intern Med. 2014 Nov 4;161(9):680.

7.

Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020A.

Rutstein RM, Samson P, Fenton T, Fletcher CV, Kiser JJ, Mofenson LM, Smith E, Graham B, Mathew M, Aldrovani G; PACTG 1020A Study Team.

Pediatr Infect Dis J. 2015 Feb;34(2):162-7. doi: 10.1097/INF.0000000000000538.

8.

A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy.

Jacobson JM, Wang H, Bordi R, Zheng L, Gross BH, Landay AL, Spritzler J, Routy JP, Benson C, Aberg J, Tebas P, Haas DW, Tiu J, Coughlin K, Purdue L, Sekaly RP; AIDS Clinical Trials Group (ACTG) A5212 Protocol Team.

J Acquir Immune Defic Syndr. 2014 Aug 1;66(4):399-406. doi: 10.1097/QAI.0000000000000195.

9.

Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.

Violari A, Lindsey JC, Hughes MD, Mujuru HA, Barlow-Mosha L, Kamthunzi P, Chi BH, Cotton MF, Moultrie H, Khadse S, Schimana W, Bobat R, Purdue L, Eshleman SH, Abrams EJ, Millar L, Petzold E, Mofenson LM, Jean-Philippe P, Palumbo P.

N Engl J Med. 2012 Jun 21;366(25):2380-9. doi: 10.1056/NEJMoa1113249.

10.

Psychological factors, beliefs about medication, and adherence of youth with human immunodeficiency virus in a multisite directly observed therapy pilot study.

Garvie PA, Flynn PM, Belzer M, Britto P, Hu C, Graham B, Neely M, McSherry GD, Spector SA, Gaur AH; Pediatric AIDS Clinical Trials Group (PACTG) P1036B Team.

J Adolesc Health. 2011 Jun;48(6):637-40. doi: 10.1016/j.jadohealth.2010.09.014. Epub 2010 Dec 18.

11.

Antiretroviral treatment for children with peripartum nevirapine exposure.

Palumbo P, Lindsey JC, Hughes MD, Cotton MF, Bobat R, Meyers T, Bwakura-Dangarembizi M, Chi BH, Musoke P, Kamthunzi P, Schimana W, Purdue L, Eshleman SH, Abrams EJ, Millar L, Petzold E, Mofenson LM, Jean-Philippe P, Violari A.

N Engl J Med. 2010 Oct 14;363(16):1510-20. doi: 10.1056/NEJMoa1000931.

12.

Antiretroviral therapies in women after single-dose nevirapine exposure.

Lockman S, Hughes MD, McIntyre J, Zheng Y, Chipato T, Conradie F, Sawe F, Asmelash A, Hosseinipour MC, Mohapi L, Stringer E, Mngqibisa R, Siika A, Atwine D, Hakim J, Shaffer D, Kanyama C, Wools-Kaloustian K, Salata RA, Hogg E, Alston-Smith B, Walawander A, Purcelle-Smith E, Eshleman S, Rooney J, Rahim S, Mellors JW, Schooley RT, Currier JS; OCTANE A5208 Study Team.

N Engl J Med. 2010 Oct 14;363(16):1499-509. doi: 10.1056/NEJMoa0906626.

13.

Directly observed therapy (DOT) for nonadherent HIV-infected youth: lessons learned, challenges ahead.

Gaur AH, Belzer M, Britto P, Garvie PA, Hu C, Graham B, Neely M, McSherry G, Spector SA, Flynn PM; Pediatric AIDS Clinical Trials Group P1036B Team.

AIDS Res Hum Retroviruses. 2010 Sep;26(9):947-53. doi: 10.1089/aid.2010.0008.

14.

Randomized controlled trial of feeding a concentrated formula to infants born to women infected by human immunodeficiency virus.

Winter HS, Oleske JM, Hughes MD, McKinney RE Jr, Elgie C, Powell C, Purdue L, Puga AM, Jimenez E, Scott GB, Cruz ML, Moye J Jr; Pediatric AIDS Clinical Trials Group Protocol 247 Study Team.

J Pediatr Gastroenterol Nutr. 2009 Aug;49(2):222-32. doi: 10.1097/MPG.0b013e3181928937.

15.

A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy.

Gandhi RT, O'Neill D, Bosch RJ, Chan ES, Bucy RP, Shopis J, Baglyos L, Adams E, Fox L, Purdue L, Marshak A, Flynn T, Masih R, Schock B, Mildvan D, Schlesinger SJ, Marovich MA, Bhardwaj N, Jacobson JM; AIDS Clinical Trials Group A5130 team.

Vaccine. 2009 Oct 9;27(43):6088-94. doi: 10.1016/j.vaccine.2009.05.016. Epub 2009 May 29.

16.

Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy.

Chadwick EG, Pinto J, Yogev R, Alvero CG, Hughes MD, Palumbo P, Robbins B, Hazra R, Serchuck L, Heckman BE, Purdue L, Browning R, Luzuriaga K, Rodman J, Capparelli E; International Maternal Pediatric Adolescent Clinical Trials Group (IMPAACT) P1030 Team.

Pediatr Infect Dis J. 2009 Mar;28(3):215-9. doi: 10.1097/INF.0b013e31818cc053.

17.

Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353.

Bryson YJ, Mirochnick M, Stek A, Mofenson LM, Connor J, Capparelli E, Watts DH, Huang S, Hughes MD, Kaiser K, Purdue L, Asfaw Y, Keller M, Smith E; PACTG 353 Team.

HIV Clin Trials. 2008 Mar-Apr;9(2):115-25. doi: 10.1310/hct0902-115.

18.

Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068.

Jacobson JM, Pat Bucy R, Spritzler J, Saag MS, Eron JJ Jr, Coombs RW, Wang R, Fox L, Johnson VA, Cu-Uvin S, Cohn SE, Mildvan D, O'Neill D, Janik J, Purdue L, O'Connor DK, Vita CD, Frank I; National Institute of Allergy and Infectious Diseases-AIDS Clinical Trials Group 5068 Protocol Team.

J Infect Dis. 2006 Sep 1;194(5):623-32. Epub 2006 Aug 1.

PMID:
16897661
19.

Intranasal sumatriptan for prevention of post-ECT headaches.

White PF, Purdue L, Downing M, Thornton L.

Headache. 2006 Apr;46(4):692. No abstract available.

PMID:
16643571
20.

A study of the immunology, virology, and safety of prednisone in HIV-1-infected subjects with CD4 cell counts of 200 to 700 mm(-3).

Wallis RS, Kalayjian R, Jacobson JM, Fox L, Purdue L, Shikuma CM, Arakaki R, Snyder S, Coombs RW, Bosch RJ, Spritzler J, Chernoff M, Aga E, Myers L, Schock B, Lederman MM.

J Acquir Immune Defic Syndr. 2003 Mar 1;32(3):281-6.

PMID:
12626887

Supplemental Content

Loading ...
Support Center